Giving you all the latest in Stock Market Information as it happens...

25805,25766,25763,25760,25756,25753,25751,25747,25745,25743,

VivaGel Condom Patent

Starpharma Holdings Limited (SPL, OTCQX:SPHRY) today announced the extension of the VivaGel® patent portfolio with the first grant of its patent specifically for the VivaGel® coated condom. The application will be granted on 20th August 2010 by the Russian patent office. Starpharma has also filed this patent in major markets including the USA, Canada, Europe, China, India and Japan. Both the VivaGel® coated condom and the VivaGel® standalone gel are already protected by a portfolio of granted VivaGel® patents in major markets. This new patent family not only provides additional protection for the condom product but also extends the duration of coverage in each market for which it is granted. In the case of this grant in Russia it provides coverage for the coated condom until at least 2026. “This is an important milestone in the commercialisation of the VivaGel® coated condom,” said Dr Jackie Fairley, CEO Starpharma. “Although each patent office works according to slightly different criteria, we consider this successful grant to be a very encouraging sign more widely. Additionally, protection in Russia is very valuable in its own right as Starpharma’s commercial partner SSL has the leading position in the Russian condom market.” SSL International plc (LSE:SSL) holds approximately 40% of the global branded condom market and is the owner of Durex®, the number one global condom brand. In addition to the coated condom, Starpharma is also developing VivaGel® as a stand-alone vaginal microbicide to prevent the transmission of STIs, including HIV and genital herpes, and for the treatment of Bacterial Vaginosis.